DNAprint Genomics (DNAG)

[geob]

Frog 96%>95%.....

we already have developed a product
called OVANOME_ in collaboration with the University of Florida and the
H. Lee Moffitt Cancer Center. OVANOME is a genomic-based diagnostic tool
for matching ovarian cancer patients with the most suitable form and
dose of chemotherapy. We're particularly concentrating on patients being
treated with the drug Taxol. In previous FDA trials, Taxol-Carboplatin
drug combination therapy demonstrated efficacy in only about 60% of
patients treated. Our OVANOME therapeutic response tests have yielded
encouraging results so far. They were 96% effective in distinguishing
Taxol-Carboplatin responders from non-responders.

96% EFFECTIVE

Maybe they are only 96% satisfied....

Hope this helps Frog---GEO